ES2054719T3 - Inactivacion del virus de la inmunodeficiencia humana (vih) en soluciones con contenido de proteinas por parte de fenoles. - Google Patents

Inactivacion del virus de la inmunodeficiencia humana (vih) en soluciones con contenido de proteinas por parte de fenoles.

Info

Publication number
ES2054719T3
ES2054719T3 ES88103458T ES88103458T ES2054719T3 ES 2054719 T3 ES2054719 T3 ES 2054719T3 ES 88103458 T ES88103458 T ES 88103458T ES 88103458 T ES88103458 T ES 88103458T ES 2054719 T3 ES2054719 T3 ES 2054719T3
Authority
ES
Spain
Prior art keywords
hiv
inactivation
human immunodeficiency
solutions
phenols
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88103458T
Other languages
English (en)
Inventor
Joachim Dr Hilfenhaus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Behringwerke AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke AG filed Critical Behringwerke AG
Application granted granted Critical
Publication of ES2054719T3 publication Critical patent/ES2054719T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A61L2/0088—Liquid substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • C12N2740/16063—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE DESCRIBE UN PROCEDIMIENTO PARA LA INACTIVACION DEL VIRUS DE INMUNODEFICIENCIA HUMANA (HIV) EN SOLUCIONES DE PROTEINAS QUE SE CARACTERIZA PORQUE SE AÑADE FENOL A ESTAS SOLUCIONES DEJANDOLO ACTUAR SOBRE ELLAS. DE ESTE MODO SE PUEDEN OBTENER, POR EJEMPLO, PREPARACIONES EN CUYA APLICACION A HUMANOS QUEDE EXCLUIDA UNA TRANSMISION DEL SIDA
ES88103458T 1987-03-12 1988-03-05 Inactivacion del virus de la inmunodeficiencia humana (vih) en soluciones con contenido de proteinas por parte de fenoles. Expired - Lifetime ES2054719T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19873707987 DE3707987A1 (de) 1987-03-12 1987-03-12 Inaktivierung von human immunodeficiency virus (hiv) in proteinhaltigen loesungen durch phenole

Publications (1)

Publication Number Publication Date
ES2054719T3 true ES2054719T3 (es) 1994-08-16

Family

ID=6322881

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88103458T Expired - Lifetime ES2054719T3 (es) 1987-03-12 1988-03-05 Inactivacion del virus de la inmunodeficiencia humana (vih) en soluciones con contenido de proteinas por parte de fenoles.

Country Status (13)

Country Link
US (1) US4886779A (es)
EP (1) EP0281978B1 (es)
JP (1) JPH07106985B2 (es)
AT (1) ATE88752T1 (es)
AU (1) AU613603B2 (es)
CA (1) CA1340414C (es)
DE (2) DE3707987A1 (es)
DK (1) DK135588A (es)
ES (1) ES2054719T3 (es)
FI (1) FI881123A (es)
IE (1) IE61439B1 (es)
MX (1) MX164795B (es)
ZA (1) ZA881756B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022742A (en) 1986-11-26 2000-02-08 Kopf; Henry B. Culture device and method
FR2662353A1 (fr) * 1990-05-22 1991-11-29 Neyroud Andre Savon en pain ou liquide antiseptique puissant, qui detruit les virus du sida, assure l'hygiene corporelle et protege la peau.
GB9110808D0 (en) * 1991-05-17 1991-07-10 Retroscreen Ltd Aids vaccine and method for its production
DE10112617A1 (de) * 2001-03-14 2002-10-02 Aventis Behring Gmbh Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren
AU2011364724B2 (en) * 2011-04-08 2016-11-17 Universidad De Costa Rica Method for producing injectable formulations of blood-derived protein materials, and materials obtained using said method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL63957C (es) * 1946-01-03
DE2643213C2 (de) * 1976-09-25 1985-02-21 Bayer Ag, 5090 Leverkusen Verfahren zum Abschwächen oder Inaktivieren von Mikroorganismen
US4746508A (en) * 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
US4713240A (en) * 1985-04-04 1987-12-15 Research Corporation Vaccines based on insoluble supports
US4673733A (en) * 1985-04-11 1987-06-16 Sudhish Chandra Treatment of biological and pharmaceutical products adsorbed on a solid phase with virus and pyrogen inactivating agents
US4711876A (en) * 1985-12-05 1987-12-08 Catapano Salvatore J Process for the treatment and remission of AIDS (acquired immune deficiency syndrome)
WO1988009655A1 (en) * 1987-06-05 1988-12-15 Al Sioufi Habib Method and device for disinfecting biological fluids and container for same
US4833165A (en) * 1987-10-07 1989-05-23 Louderback Allan Lee Method of inactivating HTLV-III virus in blood

Also Published As

Publication number Publication date
ATE88752T1 (de) 1993-05-15
IE61439B1 (en) 1994-11-02
DK135588D0 (da) 1988-03-11
IE880725L (en) 1988-09-12
ZA881756B (en) 1988-08-31
DE3880533D1 (de) 1993-06-03
FI881123A0 (fi) 1988-03-10
EP0281978A2 (de) 1988-09-14
US4886779A (en) 1989-12-12
FI881123A (fi) 1988-09-13
JPH07106985B2 (ja) 1995-11-15
EP0281978B1 (de) 1993-04-28
JPS63243023A (ja) 1988-10-07
AU613603B2 (en) 1991-08-08
DE3707987A1 (de) 1988-09-22
MX164795B (es) 1992-09-24
CA1340414C (en) 1999-03-02
DK135588A (da) 1988-09-13
AU1303788A (en) 1988-09-15
EP0281978A3 (en) 1990-01-24

Similar Documents

Publication Publication Date Title
US4632980B1 (es)
PT83434B (pt) Processo de preparacao de virus recombinantes, de peptidos ou proteinas e de vacinas contra o sindroma de imunodeficiencia adquirida
DE3684363D1 (de) Phosphonylmethoxyalkyl-adeninen zur behandlung von viruskrankheiten.
ES2087156T3 (es) Metodos para la inactivacion de virus en composiciones farmaceuticas contaminadas por virus.
ES8104412A1 (es) Procedimiento para la preparacion de un hidrolizado de pro- teinas purificado.
ES2052591T3 (es) Variantes de virus lav, sus componentes de adn y de proteinas, y sus utilizaciones particularmente con fines diagnosticos y para la preparacion de composiciones inmunogenicas.
ATE77554T1 (de) Pharmazeutisches praeparat mit 3'-desoxythymidin2'-en(3'-desoxy-2',3'-didehydrothymidin) zur behandlung von patienten mit retroviralen infektionen.
ES8200082A1 (es) Procedimiento para esterilizar un agente de contraste de ra-yos x de m-carboxamido-o-yodo-n-(b-hidroxialcohil)-anilina.
ATE165345T1 (de) Sulfonsaeurederivate zur behandlung von viruserkrankungen
EP0554389A4 (en) Molecular clones of hiv-1 and uses thereof
ATE95564T1 (de) Aeusseres membranprotein f von pseudomonas aeruginosa.
ES2054719T3 (es) Inactivacion del virus de la inmunodeficiencia humana (vih) en soluciones con contenido de proteinas por parte de fenoles.
ES8503238A1 (es) Procedimiento de preparar concentrados y nutrimentos proteinicos
ES2080047T3 (es) Peptidos hiv y metodos para la deteccion de hiv.
ATA145786A (de) Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern
NZ226904A (en) Hiv-2 env protein polypeptides and their preparation and use
DE3767308D1 (de) Verwendung von sulfonamidderivaten zur herstellung eines antivirusmittels.
ES2006632A6 (es) Procedimiento de tratamiento termico de fibrinogeno.
ATE115863T1 (de) Verwendung eines immunglobulinhaltigen präparates zur prophylaxe und therapie von aids beim menschen.
ES2062990T3 (es) Vacunas, que contienen la proteina f del virus del sida.
FI99114B (fi) Menetelmä tyvikalvoproteiinien eristämiseksi ihmis- ja eläinkudoksista
ATE123036T1 (de) Methode zur in vitro diagnose von hiv-1 virus infektionen.
GB2061948A (en) Process for concentrating aqueous urea solution
ATE84070T1 (de) Varianten von lav-viren, deren dns- und proteinkomponenten und deren verwendung, insbesondere zu diagnostischen zwecken und zur herstellung von immunogenen zusammensetzungen.
MX9400210A (es) Tratamiento de infecciones virales.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 281978

Country of ref document: ES